Mutations in KLHL6 Associated With Tangible Disease Characteristics in Diffuse Large B-Cell Lymphoma
July 8th 2024Researchers found that certain mutations in KLHL6 can lead to an increase in the number of B-cell receptors, resulting in poor outcomes for patients with diffuse large B-cell lymphoma.
Read More
Data-Driven Development: How Real-World Data and AI Are Transforming Clinical Trials
July 6th 2024Real-world data and artificial intelligence (AI) are poised to revolutionize drug development by optimizing clinical trials and regulatory approvals, if data quality and patient privacy challenges are addressed.
Read More
Insights on the UK's MHRA International Recognition Procedure
The UK’s Medicine and Healthcare Products Regulatory Agency (MHRA) introduced changes to streamline its drug approval processes.
Read More
Pharmacists Play Essential Role in Managing Dupilumab for Chronic Obstructive Pulmonary Disease
July 3rd 2024As dupilumab garners positive clinical trial results in patients with chronic obstructive pulmonary disease, it is increasingly important that pharmacists educate themselves on the treatment.
Read More
Odronextamab Demonstrates Durable Responses in Patients With R/R FL, DLBCL in Ongoing Trial
July 2nd 2024The results are promising for patients with relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma, and the trial is ongoing to assess the efficacy of odronextamab in other subtypes.
Read More